Jörg Dietrich1, Daphne Wang, Tracy T Batchelor. 1. Stephen E and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
Abstract
BACKGROUND: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. OBJECTIVE: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase. METHODS: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas. RESULTS/ CONCLUSION: Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.
BACKGROUND: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. OBJECTIVE: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase. METHODS: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas. RESULTS/ CONCLUSION:Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.
Authors: Kathy D Miller; Michael Miller; Sanjana Mehrotra; Beamon Agarwal; Bruce H Mock; Qi-Huang Zheng; Sunil Badve; Gary D Hutchins; George W Sledge Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Shideng Bao; Qiulian Wu; Sith Sathornsumetee; Yueling Hao; Zhizhong Li; Anita B Hjelmeland; Qing Shi; Roger E McLendon; Darell D Bigner; Jeremy N Rich Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: R A Goodlad; A J Ryan; S R Wedge; I T Pyrah; D Alferez; R Poulsom; N R Smith; N Mandir; A J Watkins; R W Wilkinson Journal: Carcinogenesis Date: 2006-06-16 Impact factor: 4.944
Authors: James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman Journal: Clin Cancer Res Date: 2007-02-15 Impact factor: 12.531
Authors: Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin Journal: NMR Biomed Date: 2012-07-08 Impact factor: 4.044
Authors: William L Dahut; Ravi A Madan; Joyson J Karakunnel; David Adelberg; James L Gulley; Ismail B Turkbey; Cindy H Chau; Shawn D Spencer; Marcia Mulquin; John Wright; Howard L Parnes; Seth M Steinberg; Peter L Choyke; William D Figg Journal: BJU Int Date: 2013-02-18 Impact factor: 5.588
Authors: Tianli Wang; Rajneet K Oberoi; William F Elmquist Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-10-29 Impact factor: 3.205
Authors: Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys Journal: Clin J Am Soc Nephrol Date: 2010-01-07 Impact factor: 8.237
Authors: Inmaculada Spiteri; Andrea Sottoriva; Sara Gm Piccirillo; Anestis Touloumis; Suzan Ber; Stephen J Price; Richard Heywood; Nicola-Jane Francis; Karen D Howarth; Vincent P Collins; Ashok R Venkitaraman; Christina Curtis; John C Marioni; Simon Tavaré; Colin Watts Journal: Cancer Res Date: 2014-11-18 Impact factor: 12.701